DexCom, Inc. (NASDAQ:DXCM) EVP Matthew Vincent Dolan Sells 1,990 Shares

DexCom, Inc. (NASDAQ:DXCM) EVP Matthew Vincent Dolan sold 1,990 shares of the stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the sale, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at $5,839,974.37. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

DexCom Trading Down 1.9 %

Shares of DexCom stock opened at $133.86 on Thursday. DexCom, Inc. has a 52-week low of $74.75 and a 52-week high of $142.00. The stock’s 50-day simple moving average is $129.20 and its 200 day simple moving average is $116.28. The stock has a market capitalization of $51.61 billion, a P/E ratio of 102.18, a P/E/G ratio of 2.31 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.07. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The business had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same period in the previous year, the business posted $0.34 EPS. The firm’s quarterly revenue was up 26.9% compared to the same quarter last year. As a group, research analysts anticipate that DexCom, Inc. will post 1.76 EPS for the current year.

Institutional Investors Weigh In On DexCom

Hedge funds and other institutional investors have recently modified their holdings of the stock. KB Financial Partners LLC bought a new stake in shares of DexCom during the first quarter valued at about $72,000. Bartlett & CO. Wealth Management LLC bought a new stake in shares of DexCom during the fourth quarter valued at about $27,000. DSM Capital Partners LLC bought a new stake in shares of DexCom during the fourth quarter valued at about $28,000. Riverview Trust Co bought a new stake in shares of DexCom during the first quarter valued at about $32,000. Finally, Valley National Advisers Inc. increased its position in shares of DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on DXCM shares. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Royal Bank of Canada started coverage on DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price for the company. UBS Group raised their target price on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Citigroup raised their target price on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Finally, Raymond James raised their target price on DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 23rd. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $141.40.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.